2012-09-18 07:58:38 - New Pharmaceuticals market report from Global Markets Direct: "High Triglyceridemia - Pipeline Review, H2 2012"

Global Markets Direct's, 'High Triglyceridemia - Pipeline Review, H2 2012', provides an overview of the High Triglyceridemia therapeutic pipeline. This report provides information on the therapeutic development for High Triglyceridemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for High Triglyceridemia. 'High Triglyceridemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463750_high_triglyceridemia_pipeline_review_ ..


Note*: Certain sections in the report may be removed or altered based

on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for High Triglyceridemia.
* A review of the High Triglyceridemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the High Triglyceridemia pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of High Triglyceridemia therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

High Triglyceridemia Therapeutic Products under Development, Key Players in High Triglyceridemia Therapeutics, High Triglyceridemia Pipeline Overview, High Triglyceridemia Pipeline, High Triglyceridemia Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
High Triglyceridemia Overview
Therapeutics Development
An Overview of Pipeline Products for High Triglyceridemia
High Triglyceridemia Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
High Triglyceridemia Therapeutics - Products under Development by Companies
Companies Involved in High Triglyceridemia Therapeutics Development
Isis Pharmaceuticals, Inc.
Novartis AG
Amylin Pharmaceuticals, Inc.
Amarin Corporation plc
Spherix Incorporated
Catabasis Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc.
Essentialis, Inc.
High Triglyceridemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Vascepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-APOCIII - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDX-085 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CaPre - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diazoxide Choline Controlled Release - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epanova - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diazoxide Choline Controlled Release + Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCQ-908 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metreleptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FXR-Agonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKR-963 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPX-106 + D-Tagatose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAT-2000 - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463750&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.